AIM ImmunoTech Inc. SEC 10-Q Report

AIM ImmunoTech Inc., a biotechnology company focused on the development of immune-modulatory therapies, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational progress, highlighting key metrics and strategic initiatives. Financial Highlights Total Revenues: AIM ImmunoTech reported total revenues of $26 thousand for the three months ended September 30, 2025, and $67 thousand for the nine months ended September 30, 2025. This represents a decrease compared to the same periods in 2024.Operating Loss: The company recorded an operating loss of $(2,447) thousand for the three months ended September 30, 2025, and $(8,712) thousand for the nine months ended September 30, 2025. This indicates a reduction in operating loss compared to the same periods in 2024.Net Loss: AIM ImmunoTech's net loss was $(3,284) thousand for the three months ended September 30, 2025, and $(9,783) thousand for the nine months ended September 30, 2025, showing a decrease in net loss compared to the same periods in 2024.Basic and Diluted Loss Per Share: The basic and diluted loss per share was $(1.57) for the three months ended September 30, 2025, and $(8.18) for the nine months ended September 30, 2025, reflecting an improvement compared to the same periods in 2024. Business Highlights Product Development Focus: AIM ImmunoTech is prioritizing the development of its flagship product, Ampligen, for various applications including the treatment of pancreatic cancer, multiple cancers as a tumor microenvironment modifier, antiviral activities, and as a treatment for ME/CFS and Post-COVID conditions.Geographical Performance: Ampligen is approved for commercial sale in Argentina for the treatment of severe Chronic Fatigue Syndrome (CFS). However, economic conditions have impacted its market viability. The company is focusing efforts on obtaining approval for pancreatic cancer treatment in Argentina.Clinical Trials and Research: The company is conducting clinical trials to evaluate Ampligen's efficacy and safety in treating pancreatic cancer and other solid tumors. It is also exploring Ampligen's potential as a vaccine adjuvant in combination with AstraZeneca’s FluMist for influenza.Operational Strategy: AIM is focusing on clinical activities authorized by the FDA or European Medicines Agency, with a priority on trials that support a potential future New Drug Application (NDA).Future Outlook: AIM plans to continue its research and development efforts, focusing on Ampligen's potential in treating various cancers and viral diseases. The company is also seeking collaborative grants to support its clinical trials and research initiatives.SEC Filing: AIM ImmunoTech Inc. [ AIM ] - 10-Q - Nov. 17, 2025